HYBRID EVENT: You can participate in person at Tokyo, Japan or Virtually from your home or work.

5th Edition of International Conference on

Traditional Medicine, Ethnomedicine and Natural Therapies

May 22-23, 2023 | Tokyo, Japan

Traditional Medicine 2022

NRICM102 Ameliorates Pulmonary Embolism by Suppression of Inflammation, Prothrombotic/Fibrotic Factors Expression and Reduction of Alveolar Cell Apoptosis in SARS-CoV-2 Spike Protein-infected hACE2 mice

Speaker at Traditional Medicine, Ethnomedicine and Natural Therapies 2022 - Yuh Chiang Shen
National Research Institute of Chinese Medicine, Taiwan
Title : NRICM102 Ameliorates Pulmonary Embolism by Suppression of Inflammation, Prothrombotic/Fibrotic Factors Expression and Reduction of Alveolar Cell Apoptosis in SARS-CoV-2 Spike Protein-infected hACE2 mice

Abstract:

The prevalence of venous thromboembolic syndrome in hospitalized patients with COVID-19 is high. Our unpublished clinical data showed that a traditional Chinese medicine(TCM) NRICM101 can reduce the transfer rate of mild to moderate hospitalized patients with COVID-19 to ICU or intubation by 80% and NRICM102, another TCM remedy, can reduce mortality of severe to very severe hospitalized patients with COVID-19 by more than 50%. To examine the protective effect and mechanisms of NRICM102 on pulmonary embolism, K18-hACE2 transgenic mice infected with SARS-CoV2 spike protein S1 subunit was elucidated. NRICM102 treatment significantly ameliorated pulmonary embolism and improve arterial oxygen saturation (SO2%) from 84% to around 93%. NRICM102 could reduce S1 infection in lung tissue, ameliorate inflammatory responses by inhibiting neutrophil and macrophage activation/infiltration (MPO, Ly6G, CD11b, p65NF?B), reduce expression level of prothrombotic (NET, vWF, PAI-1) and fibrotic (c-Kit, SCF) factors and suppress AT1/AT2 alveolar cell apoptosis to achieve its lung protecting effect on this pulmonary embolism model. We conclude that NRICM102 is highly valuable and beneficial in the treatment of SARS-CoV-2 infection associated pulmonary disorders.

Biography:

Professor Yuh-Chiang Shen studied Pharmacology at Yang-Ming University, Taipei, Taiwan and received PhD degree in 1999. He joined the basic and clinical research groups at National Research Institute of Chinese Medicine, Taipei, Taiwan for promotion of traditional medicine in Taiwan for more than 20 years. He is interested in TCM for the treatment of ischemic stroke, over activity bladder, osteoarthritis, and the SARS-CoV2 related disorders, etc. He has published more than 60 research articles in SCI(E) journals.

Watsapp